Back to News
Market Impact: 0.25
Better Therapeutics Consensus Price Target Lowered by 71.43% to $1.53
Source: Nasdaq
Analyst EstimatesAnalyst Insights
The average one-year price target for Better Therapeutics (OTCPK:BTTX) was revised down 71.43% to $1.53 per share from $5.36. The aggregate analyst targets were collected as of March 14, 2024; the prior estimate was dated March 8, 2024.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.35
More News
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- UOB shares hit four-month low as Q3 profit misses analyst estimates
- Roku vp, cao Matthew Banks sells $86,906 in shares
- Palantir is dropping on earnings. Wall Street analysts remain bullish
- +49.6% since March: our AI-picked chipmaker keeps climbing after last week’s rout
- Sullivan: What the 2026 midterms could mean for energy investors